156 related articles for article (PubMed ID: 28138030)
1. The TLR3 Agonist Inhibit Drug Efflux and Sequentially Consolidates Low-Dose Cisplatin-Based Chemoimmunotherapy while Reducing Side Effects.
Ding L; Ren J; Zhang D; Li Y; Huang X; Ji J; Hu Q; Wang H; Ni Y; Hou Y
Mol Cancer Ther; 2017 Jun; 16(6):1068-1079. PubMed ID: 28138030
[TBL] [Abstract][Full Text] [Related]
2. Activation of Toll-like receptor 3 induces apoptosis of oral squamous carcinoma cells in vitro and in vivo.
Luo Q; Hu S; Yan M; Sun Z; Chen W; Chen F
Int J Biochem Cell Biol; 2012 Aug; 44(8):1266-75. PubMed ID: 22568929
[TBL] [Abstract][Full Text] [Related]
3. Functional toll-like receptor 3 expressed by oral squamous cell carcinoma induced cell apoptosis and decreased migration.
He Z; Huang X; Ni Y; Shi P; Wang Z; Han W; Hu Q
Oral Surg Oral Med Oral Pathol Oral Radiol; 2014 Jul; 118(1):92-100. PubMed ID: 24908599
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor 3-mediated tumor invasion in head and neck cancer.
Chuang HC; Huang CC; Chien CY; Chuang JH
Oral Oncol; 2012 Mar; 48(3):226-32. PubMed ID: 22070917
[TBL] [Abstract][Full Text] [Related]
5. Silencing of GLUT-1 inhibits sensitization of oral cancer cells to cisplatin during hypoxia.
Shimanishi M; Ogi K; Sogabe Y; Kaneko T; Dehari H; Miyazaki A; Hiratsuka H
J Oral Pathol Med; 2013 May; 42(5):382-8. PubMed ID: 23227892
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor 3 agonist poly I:C reinforces the potency of cytotoxic chemotherapy via the TLR3-UNC93B1-IFN-β signaling axis in paclitaxel-resistant colon cancer.
Zhao J; Xue Y; Pan Y; Yao A; Wang G; Li D; Wang T; Zhao S; Hou Y
J Cell Physiol; 2019 May; 234(5):7051-7061. PubMed ID: 30387134
[TBL] [Abstract][Full Text] [Related]
7. Osteopontin Involves Cisplatin Resistance and Poor Prognosis in Oral Squamous Cell Carcinoma.
Luo SD; Chen YJ; Liu CT; Rau KM; Chen YC; Tsai HT; Chen CH; Chiu TJ
Biomed Res Int; 2015; 2015():508587. PubMed ID: 26491674
[TBL] [Abstract][Full Text] [Related]
8. Effects of CRM197, a specific inhibitor of HB-EGF, in oral cancer.
Dateoka S; Ohnishi Y; Kakudo K
Med Mol Morphol; 2012 Jun; 45(2):91-7. PubMed ID: 22718294
[TBL] [Abstract][Full Text] [Related]
9. GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma.
Yang CZ; Ma J; Zhu DW; Liu Y; Montgomery B; Wang LZ; Li J; Zhang ZY; Zhang CP; Zhong LP
Ann Oncol; 2014 Jun; 25(6):1215-22. PubMed ID: 24669014
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D promotes the cisplatin sensitivity of oral squamous cell carcinoma by inhibiting LCN2-modulated NF-κB pathway activation through RPS3.
Huang Z; Zhang Y; Li H; Zhou Y; Zhang Q; Chen R; Jin T; Hu K; Li S; Wang Y; Chen W; Huang Z
Cell Death Dis; 2019 Dec; 10(12):936. PubMed ID: 31819048
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of β-Catenin Induces Cisplatin Resistance in Oral Squamous Cell Carcinoma.
Li L; Liu HC; Wang C; Liu X; Hu FC; Xie N; Lü L; Chen X; Huang HZ
Biomed Res Int; 2016; 2016():5378567. PubMed ID: 27529071
[TBL] [Abstract][Full Text] [Related]
12. Epiregulin reprograms cancer-associated fibroblasts and facilitates oral squamous cell carcinoma invasion via JAK2-STAT3 pathway.
Wang Y; Jing Y; Ding L; Zhang X; Song Y; Chen S; Zhao X; Huang X; Pu Y; Wang Z; Ni Y; Hu Q
J Exp Clin Cancer Res; 2019 Jun; 38(1):274. PubMed ID: 31234944
[TBL] [Abstract][Full Text] [Related]
13. Kochia scoparia induces apoptosis of oral cancer cells in vitro and in heterotopic tumors.
Han HY; Lee HE; Kim HJ; Jeong SH; Kim JH; Kim H; Ryu MH
J Ethnopharmacol; 2016 Nov; 192():431-441. PubMed ID: 27616033
[TBL] [Abstract][Full Text] [Related]
14. A novel stromal lncRNA signature reprograms fibroblasts to promote the growth of oral squamous cell carcinoma via LncRNA-CAF/interleukin-33.
Ding L; Ren J; Zhang D; Li Y; Huang X; Hu Q; Wang H; Song Y; Ni Y; Hou Y
Carcinogenesis; 2018 Mar; 39(3):397-406. PubMed ID: 29346528
[TBL] [Abstract][Full Text] [Related]
15. FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells.
Fang L; Wang H; Zhou L; Yu D
Toxicol Appl Pharmacol; 2011 Feb; 251(1):8-15. PubMed ID: 21092744
[TBL] [Abstract][Full Text] [Related]
16. Chemosensitizing effect of honokiol in oral carcinoma stem cells via regulation of IL-6/Stat3 signaling.
Chang MT; Lee SP; Fang CY; Hsieh PL; Liao YW; Lu MY; Tsai LL; Yu CC; Liu CM
Environ Toxicol; 2018 Nov; 33(11):1105-1112. PubMed ID: 30076764
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor macrophages activated by ferumoxytol combined or surface-functionalized with the TLR3 agonist poly (I : C) promote melanoma regression.
Zhao J; Zhang Z; Xue Y; Wang G; Cheng Y; Pan Y; Zhao S; Hou Y
Theranostics; 2018; 8(22):6307-6321. PubMed ID: 30613299
[TBL] [Abstract][Full Text] [Related]
18. The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma.
Feng X; Luo Q; Zhang H; Wang H; Chen W; Meng G; Chen F
J Exp Clin Cancer Res; 2017 Jun; 36(1):81. PubMed ID: 28637493
[TBL] [Abstract][Full Text] [Related]
19. Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma.
Suenaga N; Kuramitsu M; Komure K; Kanemaru A; Takano K; Ozeki K; Nishimura Y; Yoshida R; Nakayama H; Shinriki S; Saito H; Jono H
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31635163
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of a novel oral formation of 5-fluorouracil in combination with low-dose cisplatin as preoperative chemotherapy of oral squamous cell carcinoma.
Nakazawa M; Ohnishi T; Ohmae M; Chisoku H; Yui S; Iwai S; Sumi T; Fukuda Y; Kishino M; Yura Y
Int J Clin Pharmacol Res; 2005; 25(3):115-22. PubMed ID: 16366419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
